

Laralei S. Paras, State Bar No. 203319
Brian C. Johnson, State Bar No. 235965
SEVEN HILLS LLP
4 Embarcadero Center, Suite 1400
San Francisco, CA 94111
Telephone: (415) 926-7247
laralei@sevenhillslp.com
brian@sevenhillslp.com
Attorneys for Plaintiff
CENTER FOR ADVANCED PUBLIC AWARENESS

SUPERIOR COURT OF THE STATE OF CALIFORNIA
COUNTY OF SAN FRANCISCO

CENTER FOR ADVANCED PUBLIC
AWARENESS,
Plaintiff,
v.
LEICA MICROSYSTEMS, INC.; and
DOES 1-30, inclusive,
Defendants.

Case No. CGC-21-597046

[PROPOSED] CONSENT JUDGMENT

(Health & Safety Code § 25249.6 et seq. and
Code of Civil Procedure § 664.6)

Case Filed: December 9, 2021
Trial: April 28, 2025

1. **INTRODUCTION**

This Consent Judgment is entered by and between plaintiff Center for Advanced Public Awareness (“CAPA”) and defendant Leica Microsystems, Inc. (“Leica”), with CAPA and Leica each individually referred to as a “Party” and collectively, as the “Parties,” to resolve the allegations in CAPA’s July 9, 2021, 60-Day Notice of Violation in compliance with the Safe Drinking Water and Toxic Enforcement Act of 1986, Health & Safety Code § 25249.6 *et seq.* (“Proposition 65”).

1.1 The Parties

CAPA states that it is a California-based non-profit organization proceeding in the public interest pursuant to California Health & Safety Code § 25249.7(d) to ensure that chemicals known to the State of California to cause cancer and birth defects, or other reproductive harm are disclosed to consumers and end-users in California or eliminated from consumer products sold in California. Leica is a person in the course of doing business for purposes of California Health & Safety Code § 25249.11.

1.2 Consumer Product Description

CAPA alleges that Leica imports, sells, or distributes for sale in California Microscope Dust Covers containing di(2-ethylhexyl) phthalate (“DEHP”), including but not limited to the *Leica Microscope Dust Cover, DM100, DM300, DM500, DM750, SKU #13613584*. CAPA further alleges Leica does so without providing the clear and reasonable health hazard warning CAPA alleges is required by California Health & Safety Code § 25249.5 *et seq.* (“Proposition 65”). All such Microscope Dust Covers containing DEHP are referred to hereinafter as the “Products.” DEHP is listed pursuant to Proposition 65 as a chemical known to the State of California to cause cancer and birth defects or other reproductive harm.

1.3 Notice of Violation

CAPA served Leica, the Office of the California Attorney General (“OAG”), and all requisite public enforcement agencies with a 60-Day Notice of Violation (“Notice”) on July 9, 2021. In its Notice CAPA alleges Leica violated Proposition 65 by failing to warn its customers and consumers in California the Products can expose users to DEHP. No public enforcer has commenced and is diligently prosecuting an action to enforce the allegations set forth in the Notice.

1.4 Complaint

On December 9, 2021, CAPA commenced the instant action (“Complaint”), naming Leica as a defendant for the alleged violations of Proposition 65 that are the subject of the Notice.

1.5 No Admission

Leica denies the material, factual and legal allegations contained in the Notice and Complaint and maintains that all products it sold or distributed for sale in California, including the Products, comply with all laws. Neither any term of this Consent Judgment nor Leica’s compliance with its terms shall be deemed an admission by Leica of any fact, finding, legal issue or conclusion, or violation of law. This Section shall not, however, diminish or otherwise affect Leica’s obligations, responsibilities, and duties under this Consent Judgment.

1.6 Jurisdiction

For purposes of this Consent Judgment only, the Parties stipulate that this Court has jurisdiction over Leica as to the allegations in the Complaint; that venue is proper in the Superior Court for the County of Santa Clara; and that the Court has jurisdiction pursuant to Code of Civil Procedure § 664.6 to retain jurisdiction to oversee and enforce the provisions of this Consent Judgment.

1.7 Effective Date

The term “Effective Date” means the date on which the Court enters an order approving this Consent Judgment and enters Judgment pursuant to its terms as contemplated by Section 10, below.

2. INJUNCTIVE RELIEF: REFORMULATION, WARNINGS AND NOTIFICATION

2.1 Reformulation Commitment

Commencing on the Effective Date and continuing thereafter, all Products Leica manufactures, imports, packages, sells, ships, provides, or distributes for sale in or into California, directly or through third-party customers Leica knows or reasonably should know offer the Products for sale in or into California, shall either qualify as Reformulated Products, as defined by Section 2.2, or be accompanied by a clear and reasonable warning pursuant to Section 2.3.


2.2 Reformulation Standard

For purposes of this Consent Judgment, “Reformulated Products” are defined as Products containing DEHP in a maximum concentration of 0.1 percent (1,000 parts per million) in any “accessible component” (i.e., any component that may be touched during a reasonably foreseeable use) when analyzed by a laboratory accredited by the State of California, a federal agency, or a nationally recognized accrediting organization. For purposes of compliance with this reformulation standard, testing samples shall be prepared and extracted using Consumer Product Safety Commission (“CPSC”) methodology CPSC CH-C1001.09.4 and analyzed using U.S. Environmental Protection Agency methodology 8270D, or other methodologies utilized by federal or state government agencies to determine phthalate content in a solid substance.


2.3 Clear and Reasonable Warnings

Commencing on the Effective Date and continuing thereafter, for all Products that are not Reformulated Products as defined by Section 2.2, above, Leica shall provide clear and reasonable warnings in accordance with this Section and pursuant to Title 27 California Code of Regulations § 25600, et seq. Each warning shall be prominently placed with such conspicuousness as compared with other words, statements, designs, or devices as to render it likely to be read and understood by an ordinary individual under customary conditions before purchase or use and shall be provided in a manner such that it is clearly associated with the specific Product to which the warning applies.

(a) **Long-Form Warnings.** The Warning shall consist of the following statement:

 **WARNING:** This product can expose you to chemicals including di(2-ethylhexyl)phthalate, which is known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

(b) **Short-Form Warnings.** Leica may, but is not required to, use the following short-form warnings as set forth in this subsection 2.3(b) (“Short-Form Warning”), subject to the additional requirements in Sections 2.4 and 2.5, below, as follows:

 **WARNING [or] CA WARNING [or] CALIFORNIA WARNING:** Risk of cancer and reproductive harm from exposure to di(2-ethylhexyl)phthalate. See www.P65Warnings.ca.gov.

- Or -

1 **⚠ WARNING [or] CA WARNING [or] CALIFORNIA WARNING:** Can expose
2 you to di(2-ethylhexyl)phthalate, a carcinogen and reproductive toxicant. See
3 www.P65Warnings.ca.gov.

4 - Or -

5 The following warning statement may be used on Products containing DEHP
6 manufactured and labeled prior to January 1, 2028:

7 **⚠ WARNING:** Cancer and Reproductive Harm – www.P65Warnings.ca.gov

8 **(c) Foreign Language Requirement.** Where a consumer product sign, label or shelf tag
9 used to provide a warning includes consumer information in language(s) other than English, the
10 warning must also be provided in the other language(s) in addition to English.

11 **2.4 Product Warnings**

12 Commencing on the Effective Date and continuing thereafter, for all Products sold and/or
13 offered for sale in California that do not meet the definition of “Reformulated Products” established
14 by Section 2.2, above. Leica shall affix a warning to the Product label, packaging, or otherwise
15 directly on Products provided for sale to consumers in California and to customers Leica knows or
16 reasonably should know offer internet sales, maintain retail outlets in California or engage in
17 nationwide distribution. For purposes of this Agreement, “Product label” means any display of
18 written, printed or graphic material printed on or affixed to a Product or its immediate container or
19 packaging. A warning provided pursuant to section 2.3(a) or (b) must print the word “**WARNING:**”
20 in all capital letters and in bold font. The warning symbol to the left of the word “**WARNING:**”
21 must be a black exclamation point in a yellow equilateral triangle with a black outline, except if the
22 labeling does not use yellow, the symbol may be in black and white. The entire warning shall appear
23 in at least 6-point type and no smaller than the largest type size used for other consumer information
24 on the Products.

25 **2.5 Internet Warnings**

26 If, after the Effective Date, Leica sells Products other than Reformulated Products via the
27 internet, through its own website(s), affiliated websites or a third-party website Leica knows or
28 reasonably should know sells Products online directly to California consumers, or to customers with

1 retail outlets located in California or that offer nationwide distribution, Leica shall provide warnings
2 for each Product both on the Product label in accordance with Section 2.4, and by prominently
3 displaying, or requiring the warning to be prominently displayed to the consumer during the purchase
4 of the Product without requiring customers to seek out the warning. The warning or a clearly marked
5 hyperlink to the warning using the word “**WARNING**” given in conjunction with the sale of Products
6 via the internet shall appear on the same web page on which the Products are displayed. The warning
7 shall appear in the same type size or larger than other consumer information provided for the Product.
8 For its third-party customers that Leica knows or reasonably should know offer the Products for sale in
9 or into California via the internet, Leica shall notify such sellers the Products must be accompanied by
10 a warning, prior to and as a condition of sale to California consumers, and shall supply the warning
11 requirements, pursuant to this Section 2.

12 **3. MONETARY SETTLEMENT TERMS**

13 **3.1 Civil Penalty**

14 Pursuant to Health and Safety Code § 25249.7(b), Leica agrees to pay a civil penalty of
15 \$3,000 within ten (10) days of the Effective Date. Leica’s civil penalty payment will be allocated
16 according to Health and Safety Code § 25249.12(c)(1) and (d), with seventy-five percent (75%) of the
17 penalty paid to the California Office of Environmental Health Hazard Assessment (“OEHHA”), and
18 the remaining twenty-five percent (25%) retained by CAPA. Leica shall issue its payment in two
19 checks made payable to: (a) “OEHHA” in the amount of \$2,250; and (b) “Seven Hills LLP in trust for
20 Center for Advanced Public Awareness” in the amount of \$750. CAPA’s counsel shall deliver to
21 OEHHA and CAPA their respective portions of the penalty payment.

22 **3.2 Reimbursement of Attorneys’ Fees and Costs**

23 The Parties negotiated Leica’s reimbursement of a portion of CAPA’s attorneys’ fees and
24 costs under general contract principles and the private attorney general doctrine, codified at California
25 Code of Civil Procedure § 1021.5. The negotiated reimbursement includes all work performed
26 through the mutual execution and reporting of this Consent Judgment to the OAG and obtaining an
27 entry of Judgment by the Court pursuant its terms, but exclusive of fees and costs on appeal, if any.
28 Within ten (10) days of the Effective Date, Leica shall issue a check for \$29,000, payable to “Seven

Hills LLP” for all fees and costs incurred investigating, bringing this matter to Leica’s attention, litigating, negotiating a settlement, obtaining the Court’s approval of its terms pursuant to Section 5, and reporting the Parties’ settlement to the OAG.

3.3 Payments

All payments payable and due under this Consent Judgment shall be delivered to CAPA’s counsel at the following address:

Seven Hills LLP
Attn: Laralei Paras, Esq.
4 Embarcadero Center, Suite 1400
San Francisco, CA 94111

4. CLAIMS COVERED AND RELEASED

4.1 CAPA’s Release of Proposition 65 Claims

This Consent Judgment is a full, final, and binding resolution of the claims that were or could have been asserted by CAPA arising out of the allegations in the Notice and in the Complaint. CAPA, acting on its own behalf, in the public interest, and on behalf of its past and current agents, representatives, attorneys, successors and assignees (“Releasers”) releases Leica, its past and present parents, subsidiaries, affiliated entities under common ownership, directors, officers, employees, attorneys, and each entity to whom Leica directly or indirectly distributes or sells the Products including, but not limited to, its downstream distributors, wholesalers, marketplace hosts, customers, retailers, franchisees, cooperative members, and licensees (“Releasees”) based on the failure to provide a clear and reasonable warning under Proposition 65 about actual or alleged exposures to DEHP in Products distributed, sold and/or offered for sale in California before the Effective Date, as set forth in the Notice and Complaint. The Parties further agree that compliance with Section 2 of this Consent Judgment shall be deemed compliance with Proposition 65 with respect to exposures to DEHP in the Products.

The Parties further understand and agree this Section 4.1 release shall not extend (i) upstream to any entity who supplied the Products, or any component part thereof, to Leica or (ii) downstream to any individual or entity instructed by Leica, pursuant to Section 2.3 through 2.5, above, to provide a warning for the Products and who fails to do so. Nothing in this Section 4.1 release shall affect

CAPA's right to commence or prosecute an action under Proposition 65 against a Releasee that does not involve Leica's Products.

4.2 CAPA's Individual Release of Claims

CAPA, in its individual capacity as a nonprofit corporation only and not in its representative capacity, also hereby provides a release to Leica and the Releasees which shall be effective as a full and final accord and satisfaction, as a bar to all actions, causes of actions, obligations, costs, expenses, attorneys' fees, damages, losses, claims, liabilities and demands of CAPA of any nature, character, or kind arising out of alleged or actual exposures to DEHP in Products sold or distributed for sale in or into California by Leica prior to the Effective Date.

The Parties further understand and agree this Section 4.2 release shall not extend (i) upstream to any entity who supplied the Products, or any component part thereof, to Leica or (ii) downstream to any individual or entity instructed by Leica, pursuant to Section 2.3 through 2.5, above, to provide a warning for the Products and who fails to do so. Nothing in this Section 4.2 release shall affect CAPA's right to commence or prosecute an action under Proposition 65 against a Releasee that does not involve Leica's Products.

4.3 Leica's Release of CAPA

Leica, on its own behalf and on behalf of its past and current agents, representatives, attorneys, successors, and assignees, hereby waives all claims against CAPA and its attorneys and other representatives, for any actions taken or statements made (or those that could have been taken or made) by CAPA and its attorneys and other representatives, whether in the course of investigating claims or otherwise seeking to enforce Proposition 65 against it in this matter with respect to the Products.

5. COURT APPROVAL

Pursuant to California Health and Safety Code § 25249.7(f)(4), CAPA shall file a noticed motion for judicial approval of this Consent Judgment. The Parties agree to mutually employ their best efforts, and those of their counsel, to support the entry of a judgment pursuant to the terms of this Consent Judgment, and to judicial approval of their settlement in a timely manner. For purposes of

this section, “best efforts” shall include, at a minimum, supporting the motion for approval, responding to any third-party objection, and appearing at the hearing before the Court if so requested.

6. SEVERABILITY

If, subsequent to the Court’s approval and entry of this Consent Judgment as a judgment, any provision of this Consent Judgment is deemed by a court to be unenforceable, the validity of the remaining provisions shall not be adversely affected.

7. GOVERNING LAW

The terms of this Consent Judgment shall be governed by the laws of the State of California and apply within California. If Proposition 65 is repealed, preempted, or otherwise rendered inapplicable by reason of law generally, or as to the Products, then Leica may seek to modify this Consent Judgment pursuant to Section 12, below. Nothing in this Consent Judgment shall be interpreted to relieve Leica from its obligation to comply with any applicable state or federal law or regulation.

8. NOTICE

Unless specified herein, all correspondence and notice required by this Consent Judgment shall be in writing and sent by: (i) first-class registered or certified mail, return receipt requested; or (ii) a recognized overnight courier to any Party by the other at the following addresses:

For Leica Microsystems:

Leica Microsystems Inc.
Attn. of Senior Legal Counsel
LMS Americas
10 Parkway N, Suite 300
Deerfield, IL 60015

For CAPA:

Kimberly Gates Johnson, Esq.
Seven Hills LLP
4 Embarcadero Center, Suite 1400
San Francisco, CA 94111

With a copy to:

Gary M. Roberts, Esq.
Dentons US LLP
601 South Figueroa Street, Suite 2500
Los Angeles, CA 90017-5704

Any Party may, from time to time, specify in writing to the other Party a change of address to which all notices and other communications shall be sent.

1 **9. COUNTERPARTS AND ELECTRONIC SIGNATURES**

2 This Consent Judgment may be executed in counterparts and by electronic or facsimile
3 signature(s), each of which shall be deemed an original and, all of which, when taken together, shall
4 constitute one and the same document.

5 **10. COMPLIANCE WITH REPORTING REQUIREMENTS**

6 CAPA and its counsel agree to comply with the reporting form requirements referenced in
7 California Health and Safety Code § 25249.7(f).

8 **11. ENTIRE AGREEMENT**

9 This Consent Judgment contains the sole and entire agreement and understanding of the
10 Parties with respect to the entire subject matter hereof, and any and all prior discussions, negotiations,
11 commitments, or understandings, if any, are hereby merged. No warranty, representation or other
12 agreement between the Parties exists except as expressly set forth herein. No representation, oral or
13 otherwise, express or implied, other than those specifically referred to in this Consent Judgment have
14 been made by any Party. No other agreement not specifically contained herein, shall be deemed to
15 exist or to bind either of the Parties hereto.

16 **12. MODIFICATION**

17 This Consent Judgment may be modified only by: (i) a written agreement of the Parties and
18 the entry of a modified Consent Judgment by the Court thereon; or (ii) upon a successful motion of
19 any Party and the entry of a modified Consent Judgment by the Court thereon. No Party shall seek
20 modification of this Consent Judgment without first providing written notice to the other Party of the
21 basis for the modification sought, and meeting and conferring in good faith for a period of not less
22 than thirty (30) days prior to moving the Court for an order modifying the Consent Judgment. In the
23 event the Parties or either Party seek(s) modification of this Consent Judgment by written agreement
24 or on noticed motion by the Court, the Party or Parties shall provide the OAG with no less than 45
25 days' notice of their intended revision(s) to the Consent Judgment prior to any hearing by the Court
26 on a motion for approval of such modification.

13. AUTHORIZATION

The undersigned are authorized to execute this Consent Judgment on behalf of their respective Party and have read, understand, and agree to all the terms and conditions of this Consent Judgment.

AGREED TO:

AGREED TO:

Date: _____

4/16/2025 | 05:25:24 PDT
Date: _____

By: _____
Linda Rose-Droubay, CEO
CENTER FOR ADVANCED PUBLIC
AWARENESS

Signed by:
Shaza Alzaim
By: _____
16C75E7C6790410
Shaza Alzaim, Senior Counsel
LMS Americas for
LEICA MICROSYSTEMS, INC.

4/16/2025 | 05:27:48 PDT

DocuSigned by:
Manjot Deol
7918951361D64C9...

Manjot Deol

VP/GM Vertrieb & Service

1 **13. AUTHORIZATION**

2 The undersigned are authorized to execute this Consent Judgment on behalf of their respective
3 Party and have read, understand, and agree to all the terms and conditions of this Consent Judgment.


4 **AGREED TO:**

AGREED TO:

5 06/10/2025

6 Date: _____

Date: _____

7 By:  _____

By: _____

8 Linda Rose-Droubay, CEO
9 CENTER FOR ADVANCED PUBLIC
10 AWARENESS

Shaza Alzaim, Senior Counsel
LMS Americas for
LEICA MICROSYSTEMS, INC.